KPRX — Kiora Pharmaceuticals Share News
0.000.00%
Last trade - 00:00Brief: Kiora Pharmaceuticals Says Recent Strategic Partnership And Financing Expected To Fund Operations Through 2026
Kiora Pharmaceuticals Inc expected to post a loss of 42 cents a share - Earnings Preview
Brief: Kiora Pharmaceuticals Inc Files For Shelf Of Up To 76.5 Million Shares Of Common Stock By Selling Stockholders - SEC Filing
Brief: Kiora Pharmaceuticals On Jan 25, Got Into Exclusive License Deal With Théa Open Innovation Sas
Kiora Pharmaceuticals Inc expected to post a loss of 35 cents a share - Earnings Preview
Brief: Kiora Pharmaceuticals Inc Says Praveen Tyle To Be Appointed Chairman Of The Board
Brief: Kiora Pharmaceuticals Inc Adjourns Special Meeting Of Stockholders To September 27
Kiora Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Kiora Pharmaceuticals Inc expected to post a loss of $1.07 a share - Earnings Preview
Brief: Kiora Pharmaceuticals Says Received Notice Of Delisting From Nasdaq
Brief: Kiora Pharmaceuticals, Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement For KIO-201
Brief: Lind Global Fund II Reports 9.9% Passive Stake In Kiora Pharmaceuticals
Brief: Kiora Pharmaceuticals Posts Q1 Net Loss Of $1.9 Mln
Brief: Kiora's Investigational Treatment For Retinitis Pigmentosa, Kio-301, Demonstrates Visual Function Restoration In Patients Who Are Blind
Brief: Kiora Pharmaceuticals Says For 2023, Goal Is To Attract Required Capital To Invest Across Three Planned Clinical Trials For Kio-301, Kio-201 And Kio-101
U.S. STOCKS ON THE MOVE-Sweetgreen, Zoom Video, Progyny
U.S. STOCKS ON THE MOVE-Royal Caribbean, Bed Bath & Beyond, KKR
U.S. STOCKS ON THE MOVE-Kiora, SelectQuote, IronNet
Kiora rises on nod to start mid-stage study of eye drug